Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE) — Stella

Home/Epilepsy, Drug Resistant/Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)

View on ClinicalTrials.gov

Recruiting

Back to Epilepsy, Drug Resistant trials

Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Xuanwu Hospital, Beijing

Key details

Phase

Very early testing

Sponsor

Xuanwu Hospital, Beijing

Collaborators

Peking University

Enrollment target

~15 participants

Started

December 2024

Primary completion

December 2027

Age range

18 Years – 60 Years

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.